ABSTRACT
Introduction
Acute renal failure is associated with significant morbidity and mortality rates.
(1,2) Need for dialysis is an independent risk factor for early mortality after complicated cardiac surgery. (3, 4) The pathogenesis of postoperative acute renal failure is believed to be predominantly a consequence of renal hypoperfusion and ischemia, particularly of the renal medulla. (5) Several therapeutic strategies for preserving renal function after cardiac surgery have been investigated, (6) (7) (8) (9) (10) (11) (12) but to date none have been proven effective. Brain natriuretic peptide (BNP) is currently being investigated in the perioperative management of cardiac surgery patients and may be especially beneficial for patients with ventricular dysfunction, pulmonary hypertension, or renal dysfunction. Measured BNP levels can be used to predict postoperative complications and the risk of further cardiac events in cardiac surgery. (13) (14) (15) Nesiritide is a recombinant B-type natriuretic peptide that is structurally identical to the endogenous hormone produced by the ventricle in response to increased wall stress, hypertrophy and volume overload. Nesiritide causes vasodilatation and may influence renal blood flow and natriuresis. It produces The following inclusion criteria were employed for potentially relevant studies: a) random allocation to treatment, b) comparison of nesiritide versus control or other treatment, c) patients undergoing adult cardiac surgery. The exclusion criteria were: a) nonparallel design (ie cross-over) randomized trials, b) duplicate publications (in this case only the article reporting the longest follow-up was abstracted), c) non-human experimental studies, and e) no outcome data. Two investigators independently assessed compliance with selection criteria and selected studies for the final analysis, with divergences finally resolved by consensus (table 1) . Baseline and outcome data were independently abstracted by several investigators with divergences resolved by consensus. Specifically, we extracted study design (including patient selection and randomization), population, clinical setting, the number of patients randomized, patients' characteristics (preoperative creatinine), serum peak creatinine values, renal replacement therapy, adverse events, mechanical ventilation, intensive care unit (ICU) stay, length of hospital stay, death. At least two separate attempts at contacting original authors were made in case of missing data. The primary end-point of our analysis was in-hospital mortality. The co-primary endpoint was the number of patients progressing to acute kidney injury (AKI) requiring at least one episode of renal replacement therapy. Secondary endpoints included peak serum creatinine levels, mechanical ventilation and the duration of ICU and hospital stay. The internal validity and risk of bias of included trials was appraised according to the Jidad score and by completing a risk of bias table. This was performed by two independent reviewers, with divergences resolved by consensus (table  2) . Two independent and experienced reviewers also appraised study quality, with divergences resolved by consensus. Binary outcomes from individual studies were analyzed in order to compute individual relative risks (RR) with pertinent 95% confidence intervals (CI), and a pooled summary effect estimate was calculated by means of a fixed effects model, except in the case of at least moderate (50%) statistical inconsistency (I 2 ) when a random effect model was used. (19) We assessed the robustness of findings from the primary analysis through a series of sensitivity analyses, including random effects model, and by withdrawing one study at a time. Statistical heterogeneity and inconsistency was measured using, respectively, Cochran Q tests and I 2 . (20 
Results
Database searches, snowballing and contacts with experts yielded a total of 9 citations. Excluding 3 non pertinent titles or abstracts, we retrieved six studies in complete form and assessed them according to the selection criteria, (22) (23) (24) (25) (26) (27) which were included in the final analysis after the correspondent authors confirmed that there was no overlapping and/or duplicate publication. Five of these 6 studies were identified through database searches, while snowballing identified the sixth study. 
Discussion
The most important result of this metaanalysis of six randomized controlled studies is that , in spite of promising initial reports on the beneficial effects of nesiritide, there is still no evidence of improvement in clinically relevant outcomes when using this drug. In particular, nesiritide does not reduce the need for renal replacement therapy, ICU stay, the length of hospital stay and the time of mechanical ventilation. Although no significant association between nesirit- ide and mortality has been found in our study, a trend suggesting lower mortality rates for patients treated with nesiritide was suggested. The 50% reduction in mortality observed in this meta-analysis, although statistically significant, could be of interest for further studies. Unfortunately, to demonstrate a reduction in mortality from 7.8 -4.6 researchers have to plan a large trial of at least 2000 patients. No systematic review regarding the efficacy of nesiritide in the specific setting of cardiac surgery has been published so far. This review is unique in looking at a meta analysis of neseritide in the post operative adult cardiac patient. Natriuretic peptides belong to a family of small proteins that play a major role in modulation of natriuresis, diuresis and vasodilatation. They counteract the activity of the renin-angiotensin-aldosterone system. They are also involved in the regulation of homeostasis, fat metabolism and long bone growth. Natriuretic peptides share a common 17-amino-acid structure and have actions that are targeted at protecting the cardiovascular system from the effect of volume overload. Secretion of the peptides is stimulated by atrial and ventricular distension, increased blood pressure, hypoxia or renal dysfunction. (16) Natriuretic peptides are systemic and renal vasodilators that also inhibit renal tubular sodium reabsorbtion and renin-angiotensin-aldosterone axis activation. (28) Nesiritide is the synthetic natriuretic peptide (recombinant BNP) which is approved for treatment of symptomatic acute decompensated heart failure. Nesiritide is a 32 amino acid peptide, similar to the naturally occurring BNP and when administred intravenously fits a two-compartment model with a rapid distribution half-life of 2 minutes. The haemodynamic effects of nesiritide, mainly consisting in the lowering of pulmonary capillary wedge pressure, and systolic blood pressure, are observed in the first 15 minutes of an infusion. (29) In studies in which patients received standard congestive heart failure therapy (diuretics, dopamine), nesiritide 
